Results presented at the VT International Symposium and simultaneously published in Circulation.
CARDIFF-BY-THE-SEA, CA and PHILADELPHIA, October 11, 2025 /PRNewswire/ — Field Medical, Inc. today announced that Traffic published the six-month results of the ventricular catheter ablation study (VCA), the first-in-human evaluation of its FieldForce™ ablation system for ventricular tachycardia (VT). The results were also presented as part of a late-breaking trial at the 20th Annual International Symposium on Ventricular Arrhythmias (VT Symposium).
Results at six months
VCAS is a prospective, multicenter feasibility trial evaluating the safety and performance of the FieldForce ablation system in patients with VT. Unlike conventional approaches, the system delivers a proprietary high-voltage, short-pulse waveform designed to penetrate dense scar tissue while minimizing thermal injury.
Main conclusions:
- 82% freedom following recurrent VT/VF or ICD therapy
- 98% off support TV/FV (episodes)
- 11.5% had a primary safety event with 0 treatment-related complications
“While this is an initial feasibility study, the six-month results are very encouraging. Achieving 82% recurrence freedom and 98% reduction in arrhythmia burden with non-thermal, tissue-selective energy is a significant result in VT therapy. Importantly, this is the first time we have seen evidence that PFA can reach deep transmural scar tissue in the ventricle, a long-standing challenge with existing energy sources. ” said Vivek Reddy, MD, co-principal investigator, lead author and electrophysiologist at Mount Sinai, New York. “These results give me cautious optimism that with continued refinement, this approach could represent an important advance in the treatment of scar-related VT.”
With breakthrough device designation from the United States Food and Drug Administration (FDA) and acceptance into the FDA’s total product life cycle (FAUCET) Pilot program, Field Medical is advancing this program toward a pivotal trial and rigorous evaluation of high-voltage focal PFA in VT.
“It is rare for initial feasibility data to be published in Trafficand it underscores both the rigor and importance of the work,” said Steven Mickelsen, MD, founder and chief technology officer of Field Medical. “Our mission has always been to unite scientific credibility and innovation. These results mark an important milestone as we continue to evaluate pulsed-field ablation for its potential to improve outcomes for patients with ventricular arrhythmias.
Looking ahead, the company is evaluating other applications of its FieldForce ablation system beyond VT and plans to present initial feasibility results in the area of atrial fibrillation (AF) at a major scientific meeting in early 2026.
About the FieldForce™ Ablation System
The FieldForce Ablation System features a single-point contact force PFA catheter with an innovative design using proprietary FieldBending™ technology to deliver targeted, brief, high-intensity electric fields. This next-generation PFA technology was designed to deliver both precise targeted lesions and large volume transmural lesions into the ventricle.
About Field Medical®Inc.
Founded in 2022, Field Medical is a clinical-stage medical technology company committed to advancing pulsed field ablation (PFA) solutions for complex cardiac arrhythmias. Its FieldForce Ablation System incorporates a focal catheter design with proprietary FieldBending energy designed to safely deliver efficient and precise ablation with the goal of improving ventricular and atrial arrhythmia treatment outcomes. In 2024, Field Medical achieved breakthrough device designation and was able to enter the market FDA TAP Pilot Program for its indication of ventricular tachycardia.
For more information, visit www.fieldmedicalinc.com and follow us LinkedInXAnd YouTube.
The FieldForce™ Ablation System is an investigational device and is limited by federal (or U.S.) law to investigational use.
Source:
Reddy VY, et al. High-voltage focal pulsed field ablation to treat scar-related ventricular tachycardia: the first VCAS trial in humans. Traffic. Published online ahead of print October 10, 2025. doi:10.1161/CIRCULATIONAHA.125.077025
CONTACT: Holly Windler, 619.929.1275, holly.windler@gmail.com
Photo – https://mma.prnewswire.com/media/2792975/Field_Medical_FieldForce__Ablation_System_Next_Generation_PFA.jpg
Logo- https://www.times24h.com/wp-content/uploads/2025/10/1760133895_655_Circulation-Releases-6-Month-Results-of-First-in-Human-VCAS-Trial-of-FieldForce.jpg
Show original content:SOURCE Field Medical, Inc.
